Cyclooxygenase inhibitors: Instrumental drugs to understand cardiovascular homeostasis and arterial thrombosis

Cardiovascular and Hematological Disorders - Drug Targets

Volumn 8, Issue 4, 2008, Pages 268-277

  Bunimov, Natalia ^a   Laneuville, Odette ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Aspirin; Cardiovascular disease; Cyclooxygenase (cox); Inflammation; Nonsteroidal anti inflammatory drugs (NSAIDS); Prostanoids

Indexed keywords

5 BROMO 2 (4 FLUOROPHENYL) 3 (4 METHYLSULFONYLPHENYL)THIOPHENE; ACETYLSALICYLIC ACID; ARACHIDONIC ACID; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; NON PRESCRIPTION DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; PROSTANOID; ROFECOXIB; SALICYLIC ACID; SALICYLIC ACID DERIVATIVE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2;

ANALGESIA; ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ARTERY THROMBOSIS; ASTHMA; BLEEDING; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CHEMICAL STRUCTURE; CHRONIC PAIN; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DRUG ANTAGONISM; DRUG DESIGN; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG RESEARCH; DRUG RESPONSE; DRUG TARGETING; DRUG TOLERABILITY; ENZYME ACTIVITY; ENZYME INHIBITION; EOSINOPHILIA; FATTY ACID SYNTHESIS; FEVER; GASTROINTESTINAL IRRITATION; GENE MUTATION; GENETIC VARIABILITY; HEART INFARCTION; HEART PROTECTION; HEMOSTASIS; HUMAN; INFLAMMATION; LOW DRUG DOSE; MORTALITY; NONHUMAN; PAIN; PHARMACOGENETICS; PRESCRIPTION; PRIMARY PREVENTION; RESPIRATORY TRACT DISEASE; RESPIRATORY TRACT INFLAMMATION; REVIEW; RHEUMATIC DISEASE; RHINITIS; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; RNA INTERFERENCE; SECONDARY PREVENTION; THROMBOCYTE AGGREGATION INHIBITION; TRANSIENT ISCHEMIC ATTACK; ANIMAL; CARDIOVASCULAR FUNCTION; DRUG EFFECT; HOMEOSTASIS; METABOLISM; PATHOPHYSIOLOGY; THROMBOSIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CARDIOVASCULAR DISEASES; CARDIOVASCULAR PHYSIOLOGICAL PHENOMENA; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; HOMEOSTASIS; HUMANS; THROMBOSIS;

EID: 60549094963     PISSN: 1871529X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152908786786250     Document Type: Review

References (178)

1. Mueller, R. L.; Scheidt, S. History of drugs for thrombotic disease. Discovery, development, and directions for the future. Circulation, 1994, 89, 432-449.
2. Maclagan, T. The Treatment of acute rheumatism by salicin. The Lancet, 1876, 107, 342-343.
3. Mann, C. C.; Plummer, M. L. In The aspirin wars: money, medicine, and 100 years of rampant competition; Harvard Business School Press: Boston, Mass, 1991;.
4. Rainsford, K. D.; Whitehouse, M. W. Are all aspirins really alike? A comparison of gastric ulcerogenicity with bio-efficacy in rats. Pharmacol. Res. Commun., 1980, 12, 85-95.
5. Piper, P. J.; Vane, J. R. Release of additional factors in anaphylaxis and its antagonism by anti-inflammatory drugs. Nature, 1969, 223, 29-35.
6. Vane, J. R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat. New Biol., 1971, 231, 232-235.
7. Gryglewski, R.; Vane, J. R. The release of prostaglandins and rabbit aorta contracting substance (RCS) from rabbit spleen and its antagonism by anti-inflammatory drugs. Br. J. Pharmacol., 1972, 45, 37-47.
8. Rainsford, K. D. Current concepts of the mechanisms of side effects of nonsteroidal antiinflammatory drugs as a basis for establishing research priorities. An experimentalist's view. J. Rheumatol. Suppl., 1988, 17, 63-70.
9. Rainsford, K. D. Anti-inflammatory drugs in the 21st century. Sub-cell. Biochem. 2007, 42, 3-27.
10. Flower, R.; Gryglewski, R.; Herbaczynska-Cedro, K.; Vane, J. R. Effects of anti-inflammatory drugs on prostaglandin biosynthesis. Nat. New Biol., 1972, 238, 104-106.
11. Ferreira, S. H.; Moncada, S.; Vane, J. R. Further experiments to establish that the analgesic action of aspirin-like drugs depends on the inhibition of prostaglandin biosynthesis. Br. J. Pharmacol., 1973, 47, 629P-630P.
12. Hamberg, M.; Samuelsson, B. Oxygenation of unsaturated fatty acids by the vesicular gland of sheep. J. Biol. Chem., 1967, 242, 5344-5354.
13. DeWitt, D. L. Prostaglandin endoperoxide synthase: regulation of enzyme expression. Biochim. Biophys. Acta, 1991, 1083, 121-134.
14. Hamberg, M.; Samuelsson, B. Detection and isolation of an endoperoxide intermediate in prostaglandin biosynthesis. Proc. Natl. Acad. Sci. USA, 1973, 70, 899-903.
15. Bergstrom, S.; Samuelsson, B. Isolation of prostaglandin E1 from human seminal plasma. Prostaglandins and related factors 11 J. Biol. Chem., 1962, 237, 3005-3006.
16. Samuelsson, B. Isolation and Identification of Prostaglandins from Human Seminal Plasma. Prostaglandins and Related Factors 18 J. Biol. Chem., 1963, 238, 3229-3234.
17. Bergstrom, S.; Danielsson, H.; Klenberg, D.; Samuelsson, B. The Enzymatic Conversion of Essential Fatty Acids into Prostaglandins. Prostaglandins and Related Factors 34 J. Biol. Chem., 1964, 239, PC4006-4008.
18. Granstrom, E. The arachidonic acid cascade. The prostaglandins, thromboxanes and leukotrienes. Inflammation, 1984, 8 Suppl., S15-25.
19. Capdevila, J. H.; Falck, J. R.; Harris, R. C. Cytochrome P450 and arachidonic acid bioactivation: molecular and functional properties of the arachidonate monooxygenase. J. Lipid Res., 2000, 41, 163-181.
20. Deems, R.; Buczynski, M. W.; Bowers-Gentry, R.; Harkewicz, R.; Dennis, E. A. Detection and quantitation of eicosanoids via high performance liquid chromatography-electrospray ionization-mass spectrometry. Methods Enzymol., 2007, 432, 59-82.
21. www.lipidmaps.org (accessed July 17, 2008).
22. Flower, R. J.; Vane, J. R. Inhibition of prostaglandin biosynthesis. Biochem. Pharmacol., 1974, 23, 1439-1450.
23. Hemler, M.; Lands, W. E. Purification of the cyclooxygenase that forms prostaglandins. Demonstration of two forms of iron in the holoenzyme. J. Biol. Chem., 1976, 251, 5575-5579.
24. Van der Ouderaa, F. J.; Buytenhek, M.; Nugteren, D. H.; Van Dorp, D. A. Purification and characterisation of prostaglandin endoperoxide synthetase from sheep vesicular glands. Biochim. Biophys. Acta, 1977, 487, 315-331.
25. Marnett, L. J.; Wlodawer, P.; Samuelsson, B. Co-oxygenation of organic substrates by the prostaglandin synthetase of sheep vesicular gland. J. Biol. Chem., 1975, 250, 8510-8517.
26. Samuelsson, B.; Granstrom, E.; Green, K.; Hamberg, M.; Hammarstrom, S. Prostaglandins. Annu. Rev. Biochem., 1975, 44, 669-695.
27. Vane, J. R. The mode of action of aspirin and similar compounds. J. Allergy Clin. Immunol., 1976, 58, 691-712.
28. Vane, J. R. Prostaglandins as mediators of inflammation. Adv. Prostaglandin Thromboxane Res., 1976, 2, 791-801.
29. Meade, E. A.; Smith, W. L.; DeWitt, D. L. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J. Biol. Chem., 1993, 268, 6610-6614.
30. DeWitt, D. L. Cox-2-selective inhibitors: The new super aspirins. Mol. Pharmacol., 1999, 55, 625-631.
31. Smith, W. L.; DeWitt, D. L.; Garavito, R. M. Cyclooxygenases: structural, cellular, and molecular biology. Annu. Rev. Biochem., 2000, 69, 145-182.
32. Rome, L. H.; Lands, M. E. Properties of a partially-purified preparation of the prostaglandin-forming oxygenase from sheep vesicular gland. Prostaglandins, 1975, 10, 813-824.
33. DeWitt, D. L.; Smith, W. L. Primary structure of prostaglandin G/H synthase from sheep vesicular gland determined from the complementary DNA sequence. Proc. Natl. Acad. Sci. USA, 1988, 85, 1412-1416.
34. Simmons, D. L.; Levy, D. B.; Yannoni, Y.; Erikson, R. L. Identification of a phorbol ester-repressible v-src-inducible gene. Proc. Natl. Acad. Sci. USA, 1989, 86, 1178-1182.
35. Kujubu, D. A.; Fletcher, B. S.; Varnum, B. C.; Lim, R. W.; Herschman, H. R. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J. Biol. Chem., 1991, 266, 12866-12872.
36. Laneuville, O.; Breuer, D. K.; Dewitt, D. L.; Hla, T.; Funk, C. D.; Smith, W. L. Differential inhibition of human prostaglandin endoperoxide H synthases-1 and -2 by nonsteroidal anti-inflammatory drugs. J. Pharmacol. Exp. Ther., 1994, 271, 927-934.
37. Smyth, C. J.; Velayos, E. E.; Amoroso, C. A Method for Measuring Swelling of Hands and Feet. Ii. Influence of New Anti-Inflammatory Drug, Indomethacin, in Acute Gout. Acta Rheumatol. Scand., 1963, 9, 306-322.
38. Winter, C. A.; Risley, E. A.; Nuss, G. W. Anti-Inflammatory and Antipyretic Activities of Indomethacin, 1-(P-Chlorobenzoyl)-5- Methoxy-2-Methylindole-3-Acetic Acid. J. Pharmacol. Exp. Ther., 1963, 141, 369-376.
39. Green, G. A. Understanding NSAIDs: from aspirin to COX-2. Clin. Cornerstone 2001, 3, 50-60.
40. Earnest, D. L. NSAID-induced gastric injury: its pathogenesis and management. Semin. Arthritis Rheum., 1990, 19, 6-10.
41. Graham, D. Y.; Chan, F. K. NSAIDs, risks, and gastroprotective strategies: current status and future. Gastroenterology, 2008, 134, 1240-1246.
42. Gans, K. R.; Galbraith, W.; Roman, R. J.; Haber, S. B.; Kerr, J. S.; Schmidt, W. K.; Smith, C.; Hewes, W. E.; Ackerman, N. R. Anti-inflammatory and safety profile of DuP 697, a novel orally effective prostaglandin synthesis inhibitor. J. Pharmacol. Exp. Ther., 1990, 254, 180-187.
43. Futaki, N.; Yoshikawa, K.; Hamasaka, Y.; Arai, I.; Higuchi, S.; Iizuka, H.; Otomo, S. NS-398, a novel non-steroidal anti-inflammatory drug with potent analgesic and antipyretic effects, which causes minimal stomach lesions. Gen. Pharmacol., 1993, 24, 105-110.
44. Buttar, N. S.; Wang, K. K. The "aspirin" of the new millennium: cyclooxygenase-2 inhibitors. Mayo Clin. Proc., 2000, 75, 1027-1038.
45. Gierse, J. K.; Hauser, S. D.; Creely, D. P.; Koboldt, C.; Rangwala, S. H.; Isakson, P. C.; Seibert, K. Expression and selective inhibition of the constitutive and inducible forms of human cyclooxygenase. Biochem. J., 1995, 305 (Pt. 2), 479-484.
46. Fu, J. Y.; Masferrer, J. L.; Seibert, K.; Raz, A.; Needleman, P. The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J. Biol. Chem., 1990, 265, 16737-16740.
47. Masferrer, J. L.; Zweifel, B. S.; Seibert, K.; Needleman, P. Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice. J. Clin. Invest., 1990, 86, 1375-1379.
48. Sano, H.; Hla, T.; Maier, J. A.; Crofford, L. J.; Case, J. P.; Maciag, T.; Wilder, R. L. In vivo cyclooxygenase expression in synovial tissues of patients with rheumatoid arthritis and osteoarthritis and rats with adjuvant and streptococcal cell wall arthritis. J. Clin. Invest. 1992, 89, 97-108.
49. Xie, W. L.; Chipman, J. G.; Robertson, D. L.; Erikson, R. L.; Simmons, D. L. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc. Natl. Acad. Sci. USA, 1991, 88, 2692-2696.
50. Hla, T.; Neilson, K. Human cyclooxygenase-2 cDNA. Proc. Natl. Acad. Sci. U S A, 1992, 89, 7384-7388.
51. Jones, D. A.; Carlton, D. P.; McIntyre, T. M.; Zimmerman, G. A.; Prescott, S. M. Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines. J. Biol. Chem., 1993, 268, 9049-9054.
52. Kennedy, B. P.; Chan, C. C.; Culp, S. A.; Cromlish, W. A. Cloning and expression of rat prostaglandin endoperoxide synthase (cyclooxygenase)-2 cDNA. Biochem. Biophys. Res. Commun., 1993, 197, 494-500.
53. Vane, J. R.; Bakhle, Y. S.; Botting, R. M. Cyclooxygenases 1 and 2. Annu. Rev. Pharmacol. Toxicol., 1998, 38, 97-120.
54. Langenbach, R.; Loftin, C. D.; Lee, C.; Tiano, H. Cyclooxygenase-deficient mice. A summary of their characteristics and susceptibilities to inflammation and carcinogenesis. Ann. N.Y. Acad. Sci., 1999, 889, 52-61.
55. Dirig, D. M.; Yaksh, T. L. Spinal synthesis and release of prostanoids after peripheral injury and inflammation. Adv. Exp. Med. Biol., 1999, 469, 401-408.
56. Tilley, S. L.; Coffman, T. M.; Koller, B. H. Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes. J. Clin. Invest., 2001, 108, 15-23.
57. Ndengele, M. M.; Cuzzocrea, S.; Esposito, E.; Mazzon, E.; Di Paola, R.; Matuschak, G. M.; Salvemini, D. Cyclooxygenases 1 and 2 contribute to peroxynitrite-mediated inflammatory pain hypersensitivity. FASEB J., 2008.
58. Yokoyama, C.; Tanabe, T. Cloning of human gene encoding prostaglandin endoperoxide synthase and primary structure of the enzyme. Biochem. Biophys. Res. Commun., 1989, 165, 888-894.
59. Shimokawa, T.; Kulmacz, R. J.; DeWitt, D. L.; Smith, W. L. Tyrosine 385 of prostaglandin endoperoxide synthase is required for cyclooxygenase catalysis. J. Biol. Chem., 1990, 265, 20073-20076.
60. Smith, W. L.; Marnett, L. J. Prostaglandin endoperoxide synthase: structure and catalysis. Biochim. Biophys. Acta, 1991, 1083, 1-17.
61. Shimokawa, T.; Smith, W. L. Prostaglandin endoperoxide synthase. The aspirin acetylation region. J. Biol. Chem., 1992, 267, 12387-12392.
62. Fletcher, B. S.; Kujubu, D. A.; Perrin, D. M.; Herschman, H. R. Structure of the mitogen-inducible TIS10 gene and demonstration that the TIS10-encoded protein is a functional prostaglandin G/H synthase. J. Biol. Chem., 1992, 267, 4338-4344.
63. Picot, D.; Loll, P. J.; Garavito, R. M. The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1. Nature, 1994, 367, 243-249.
64. Loll, P. J.; Picot, D.; Garavito, R. M. The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase. Nat. Struct. Biol., 1995, 2, 637-643.
65. Mancini, J. A.; Riendeau, D.; Falgueyret, J. P.; Vickers, P. J.; O'Neill, G. P. Arginine 120 of prostaglandin G/H synthase-1 is required for the inhibition by nonsteroidal anti-inflammatory drugs containing a carboxylic acid moiety. J. Biol. Chem., 1995, 270, 29372-29377.
66. Kurumbail, R. G.; Stevens, A. M.; Gierse, J. K.; McDonald, J. J.; Stegeman, R. A.; Pak, J. Y.; Gildehaus, D.; Miyashiro, J. M.; Penning, T. D.; Seibert, K.; Isakson, P. C.; Stallings, W. C. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature, 1996, 384, 644-648.
67. Filizola, M.; Perez, J. J.; Palomer, A.; Mauleon, D. Comparative molecular modeling study of the three-dimensional structures of prostaglandin endoperoxide H2 synthase 1 and 2 (COX-1 and COX-2). J. Mol. Graph. Model., 1997, 15, 290-300.
68. Smith, C. J.; Morrow, J. D.; Roberts, L. J.,2nd; Marnett, L. J. Differentiation of monocytoid THP-1 cells with phorbol ester induces expression of prostaglandin endoperoxide synthase-1 (COX-1). Biochem. Biophys. Res. Commun., 1993, 192, 787-793.
69. Brannon, T. S.; North, A. J.; Wells, L. B.; Shaul, P. W. Prostacyclin synthesis in ovine pulmonary artery is developmentally regulated by changes in cyclooxygenase-1 gene expression. J. Clin. Invest., 1994, 93, 2230-2235.
70. Mroske, C.; Plant, M. H.; Franks, D. J.; Laneuville, O. Characterization of prostaglandin endoperoxide H synthase-1 enzyme expression during differentiation of the megakaryocytic cell line MEG-01. Exp. Hematol., 2000, 28, 411-421.
71. Herschman, H. R. Function and regulation of prostaglandin synthase 2. Adv. Exp. Med. Biol., 1999, 469, 3-8.
72. Funk, C. D.; Funk, L. B.; Kennedy, M. E.; Pong, A. S.; Fitzgerald, G. A. Human platelet/erythroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression, and gene chromosomal assignment. FASEB J., 1991, 5, 2304-2312.
73. Xie, W.; Merrill, J. R.; Bradshaw, W. S.; Simmons, D. L. Structural determination and promoter analysis of the chicken mitogen-inducible prostaglandin G/H synthase gene and genetic mapping of the murine homolog. Arch. Biochem. Biophys., 1993, 300, 247-252.
74. Smith, W. L.; Dewitt, D. L. Prostaglandin endoperoxide H synthases-1 and -2. Adv. Immunol., 1996, 62, 167-215.
75. Smith, W. Molecular biology of prostanoid biosynthetic enzymes and receptors. Adv. Exp. Med. Biol., 1997, 400B, 989-1011.
76. Smith, W. L.; Song, I. The enzymology of prostaglandin endoperoxide H synthases-1 and -2. Prostaglandins Other Lipid Mediat., 2002, 68-69, 115-128.
77. Smith, W. L.; Langenbach, R. Why there are two cyclooxygenase isozymes. J. Clin. Invest., 2001, 107, 1491-1495.
78. Fitzpatrick, F. A. Cyclooxygenase enzymes: regulation and function. Curr. Pharm. Des., 2004, 10, 577-588.
79. Weiss, H. J.; Aledort, L. M. Impaired platelet-connective-tissue reaction in man after aspirin ingestion. Lancet, 1967, 2, 495-497.
80. O'Brien, J. R. Effects of salicylates on human platelets. Lancet, 1968, 1, 779-783.
81. Patrono, C.; Ciabattoni, G.; Patrignani, P.; Pugliese, F.; Filabozzi, P.; Catella, F.; Davi, G.; Forni, L. Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation, 1985, 72, 1177-1184.
82. Langenbach, R.; Morham, S. G.; Tiano, H. F.; Loftin, C. D.; Ghanayem, B. I.; Chulada, P. C.; Mahler, J. F.; Davis, B. J.; Lee, C. A. Disruption of the mouse cyclooxygenase 1 gene. Characteristics of the mutant and areas of future study. Adv. Exp. Med. Biol., 1997, 407, 87-92.
83. Kniss, D. A. Cyclooxygenases in reproductive medicine and biology. J. Soc. Gynecol. Investig., 1999, 6, 285-292.
84. Yu, Y.; Cheng, Y.; Fan, J.; Chen, X. S.; Klein-Szanto, A.; Fitzgerald, G. A.; Funk, C. D. Differential impact of prostaglandin H synthase 1 knockdown on platelets and parturition. J. Clin. Invest., 2005, 115, 986-995.
85. Dinchuk, J. E.; Car, B. D.; Focht, R. J.; Johnston, J. J.; Jaffee, B. D.; Covington, M. B.; Contel, N. R.; Eng, V. M.; Collins, R. J.; Czerniak, P. M. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature, 1995, 378, 406-409.
86. Mukherjee, D.; Nissen, S. E.; Topol, E. J. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA, 2001, 286, 954-959.
87. Zeidler, H. Epidemiology and economics of NSAID-induced gastropathy. Scand. J. Rheumatol. Suppl., 1992, 92, 3-8.
88. Cryer, B. NSAID gastrointestinal toxicity. Curr. Opin. Gastroenterol. 2000, 16, 495-502.
89. Laine, L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 2001, 120, 594-606.
90. Simon, L. S. Are the biologic and clinical effects of the COX-2-specific inhibitors an advance compared with the effects of traditional NSAIDs? Curr. Opin. Rheumatol., 2000, 12, 163-170.
91. Bombardier, C. An evidence-based evaluation of the gastrointestinal safety of coxibs. Am. J. Cardiol., 2002, 89, 3D-9D.
92. Seibert, K.; Zhang, Y.; Leahy, K.; Hauser, S.; Masferrer, J.; Perkins, W.; Lee, L.; Isakson, P. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc. Natl. Acad. Sci. USA, 1994, 91, 12013-12017.
93. Penning, T. D.; Talley, J. J.; Bertenshaw, S. R.; Carter, J. S.; Collins, P. W.; Docter, S.; Graneto, M. J.; Lee, L. F.; Malecha, J. W.; Miyashiro, J. M.; Rogers, R. S.; Rogier, D. J.; Yu, S. S.; AndersonGD; Burton, E. G.; Cogburn, J. N.; Gregory, S. A.; Koboldt, C. M.; Perkins, W. E.; Seibert, K.; Veenhuizen, A. W.; Zhang, Y. Y.; Isakson, P. C. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib). J. Med. Chem., 1997, 40, 1347-1365.
94. Simon, L. S.; Lanza, F. L.; Lipsky, P. E.; Hubbard, R. C.; Talwalker, S.; Schwartz, B. D.; Isakson, P. C.; Geis, G. S. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum., 1998, 41, 1591-1602.
95. Wolfe, F.; Anderson, J.; Burke, T. A.; Arguelles, L. M.; Pettitt, D. Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy. J. Rheumatol., 2002, 29, 467-473.
96. Solomon, S. D. Cyclooxygenase-2 inhibitors and cardiovascular risk. Curr. Opin Cardiol., 2006, 21, 613-617.
97. Bombardier, C.; Laine, L.; Reicin, A.; Shapiro, D.; Burgos-Vargas, R.; Davis, B.; Day, R.; Ferraz, M. B.; Hawkey, C. J.; Hochberg, M. C.; Kvien, T. K.; Schnitzer, T. J.; VIGOR Study Group Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N. Engl. J. Med., 2000, 343, 1520-8, 2 p following 1528.
98. Bresalier, R. S.; Sandler, R. S.; Quan, H.; Bolognese, J. A.; Oxenius, B.; Horgan, K.; Lines, C.; Riddell, R.; Morton, D.; Lanas, A.; Konstam, M. A.; Baron, J. A.; Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N. Engl. J. Med., 2005, 352, 1092-1102.
99. Kearney, P. M.; Baigent, C.; Godwin, J.; Halls, H.; Emberson, J. R.; Patrono, C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ, 2006, 332, 1302-1308.
100. FitzGerald, G. A.; Cheng, Y.; Austin, S. COX-2 inhibitors and the cardiovascular system. Clin. Exp. Rheumatol. 2001, 19, S31-6.
101. Fitzgerald, G. A. Coxibs and cardiovascular disease. N. Engl. J. Med., 2004, 351, 1709-1711.
102. FitzGerald, G. A. Nonsteroidal anti-inflammatory drugs, coxibs, and cardio-renal physiology: a mechanism-based approach. Am. J. Cardiol., 2002, 89, 1D-2D.
103. Grosser, T.; Fries, S.; FitzGerald, G. A. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J. Clin. Invest., 2006, 116, 4-15.
104. Flavahan, N. A. Balancing prostanoid activity in the human vascular system. Trends Pharmacol. Sci., 2007, 28, 106-110.
105. Couzin, J. Drug safety. Withdrawal of Vioxx casts a shadow over COX-2 inhibitors. Science, 2004, 306, 384-385.
106. Catella-Lawson, F.; Reilly, M. P.; Kapoor, S. C.; Cucchiara, A. J.; DeMarco, S.; Tournier, B.; Vyas, S. N.; FitzGerald, G. A. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N. Engl. J. Med., 2001, 345, 1809-1817.
107. Miner, J.; Hoffhines, A. The discovery of aspirin's antithrombotic effects. Tex. Heart Inst. J., 2007, 34, 179-186.
108. Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. N. Engl. J. Med., 1989, 321, 129-135.
109. FitzGerald, G. A.; Oates, J. A.; Hawiger, J.; Maas, R. L.; Roberts, L. J.,2nd; Lawson, J. A.; Brash, A. R. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J. Clin. Invest., 1983, 71, 676-688.
110. Pedersen, A. K.; FitzGerald, G. A. Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. N. Engl. J. Med., 1984, 311, 1206-1211.
111. Pedersen, A. K.; FitzGerald, G. A. The human pharmacology of platelet inhibition: pharmacokinetics relevant to drug action. Circulation, 1985, 72, 1164-1176.
112. Fitzgerald, D. J.; Roy, L.; Catella, F.; FitzGerald, G. A. Platelet activation in unstable coronary disease. N. Engl. J. Med., 1986, 315, 983-989.
113. Reilly, I. A.; FitzGerald, G. A. Aspirin in cardiovascular disease. Drugs, 1988, 35, 154-176.
114. Lewis, H. D.,Jr; Davis, J. W.; Archibald, D. G.; Steinke, W. E.; Smitherman, T. C.; Doherty, J. E.,3rd; Schnaper, H. W.; LeWinter, M. M.; Linares, E.; Pouget, J. M.; Sabharwal, S. C.; Chesler, E.; DeMots, H. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N. Engl. J. Med., 1983, 309, 396-403.
115. Reilly, I. A.; Doran, J. B.; Smith, B.; FitzGerald, G. A. Increased thromboxane biosynthesis in a human preparation of platelet activation: biochemical and functional consequences of selective inhibition of thromboxane synthase. Circulation, 1986, 73, 1300-1309.
116. Oates, J. A.; FitzGerald, G. A.; Branch, R. A.; Jackson, E. K.; Knapp, H. R.; Roberts, L. J.,2nd Clinical implications of prostaglandin and thromboxane A2 formation (1). N. Engl. J. Med., 1988, 319, 689-698.
117. Oates, J. A.; FitzGerald, G. A.; Branch, R. A.; Jackson, E. K.; Knapp, H. R.; Roberts, L. J.,2nd Clinical implications of prostaglandin and thromboxane A2 formation (2). N. Engl. J. Med., 1988, 319, 761-767.
118. Peto, R.; Gray, R.; Collins, R.; Wheatley, K.; Hennekens, C.; Jamrozik, K.; Warlow, C.; Hafner, B.; Thompson, E.; Norton, S.; Gilliland, J.; Doll, R. Randomised trial of prophylactic daily aspirin in British male doctors. Br. Med. J., 1988, 296, 313-316.
119. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice Research Framework. Lancet, 1998, 351, 233-241.
120. Hansson, L.; Zanchetti, A.; Carruthers, S. G.; Dahlof, B.; Elmfeldt, D.; Julius, S.; Menard, J.; Rahn, K. H.; Wedel, H.; Westerling, S. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet, 1998, 351, 1755-1762.
121. de Gaetano, G. Collaborative Group of the Primary Prevention Project Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet, 2001, 357, 89-95.
122. Ridker, P. M.; Cook, N. R.; Lee, I. M.; Gordon, D.; Gaziano, J. M.; Manson, J. E.; Hennekens, C. H.; Buring, J. E. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N. Engl. J. Med., 2005, 352, 1293-1304.
123. Bartolucci, A. A.; Howard, G. Meta-Analysis of Data from the Six Primary Prevention Trials of Cardiovascular Events Using Aspirin. Am. J. Cardiol., 2006, 98, 746-750.
124. Brinkmann, C. R.,3rd The pill doesn't poison. Science, 1969, 164, 14-15.
125. Young, F. E.; Nightingale, S. L.; Temple, R. A. The preliminary report of the findings of the aspirin component of the ongoing Physicians' Health Study. The FDA perspective on aspirin for the primary prevention of myocardial infarction. JAMA, 1988, 259, 3158-3160.
126. Thadani, U. Selection of optimal therapy for chronic stable angina. Curr. Treat. Options Cardiovasc. Med., 2006, 8, 23-35.
127. Pickering, T. G. Should hypertensive patients take aspirin? A report from the Food and Drug Administration. J. Clin. Hypertens. (Greenwich), 2004, 6, 146-149.
128. MacDonald, T. M. Epidemiology and pharmacoeconomic implications of non-steroidal anti-inflammatory drug-associated gastrointestinal toxicity. Rheumatology (Oxford), 2000, 39 Suppl. 2, 13-20; discussion 57-9.
129. Dalen, J. E. Aspirin to prevent heart attack and stroke: what's the right dose? Am. J. Med., 2006, 119, 198-202.
130. Weisman, S. M.; Graham, D. Y. Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events. Arch. Intern. Med., 2002, 162, 2197-2202.
131. Patrono, C. Unstable coronary artery disease: need for long-term antithrombotic treatment? Aspirin alone may not be the ideal antithrombotic strategy, but that's what we have adequate trial data for. Cardiovasc. Res., 1997, 33, 295-296.
132. Patrono, C.; Rocca, B. Aspirin: promise and resistance in the new millennium. Arterioscler. Thromb. Vasc. Biol., 2008, 28, s25-32.
133. MacDonald, T. M.; Wei, L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet, 2003, 361, 573-574.
134. Federman, A. D.; Litke, A.; Morrison, R. S. Association of age with analgesic use for back and joint disorders in outpatient settings. Am. J. Geriatr. Pharmacother., 2006, 4, 306-315.
135. MacDonald, T. M.; Wei, L. Is there an interaction between the cardiovascular protective effects of low-dose aspirin and ibuprofen? Basic Clin. Pharmacol. Toxicol., 2006, 98, 275-280.
136. Garcia Rodriguez, L. A.; Varas, C.; Patrono, C. Differential effects of aspirin and non-aspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women. Epidemiology, 2000, 11, 382-387.
137. Rahme, E.; Pilote, L.; LeLorier, J. Association between naproxen use and protection against acute myocardial infarction. Arch. Intern. Med., 2002, 162, 1111-1115.
138. Ray, W. A.; Stein, C. M.; Hall, K.; Daugherty, J. R.; Griffin, M. R. Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Lancet, 2002, 359, 118-123.
139. Solomon, D. H.; Glynn, R. J.; Levin, R.; Avorn, J. Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. Arch. Intern. Med., 2002, 162, 1099-1104.
140. Garcia Rodriguez, L. A.; Varas-Lorenzo, C.; Maguire, A.; Gonzalez- Perez, A. Nonsteroidal antiinflammatory drugs and the risk of myocardial infarction in the general population. Circulation, 2004, 109, 3000-3006.
141. Kimmel, S. E.; Berlin, J. A.; Reilly, M.; Jaskowiak, J.; Kishel, L.; Chittams, J.; Strom, B. L. The effects of nonselective non-aspirin non-steroidal anti-inflammatory medications on the risk of nonfatal myocardial infarction and their interaction with aspirin. J. Am. Coll. Cardiol., 2004, 43, 985-990.
142. Mamdani, M.; Rochon, P.; Juurlink, D. N.; Anderson, G. M.; Kopp, A.; Naglie, G.; Austin, P. C.; Laupacis, A. Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly. Arch. Intern. Med., 2003, 163, 481-486.
143. Solomon, D. H.; Schneeweiss, S.; Glynn, R. J.; Kiyota, Y.; Levin, R.; Mogun, H.; Avorn, J. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation, 2004, 109, 2068-2073.
144. Graham, D. J.; Campen, D.; Hui, R.; Spence, M.; Cheetham, C.; Levy, G.; Shoor, S.; Ray, W. A. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclooxygenase 2 selective and non-selective non-steroidal antiinflammatory drugs: nested case-control study. Lancet, 2005, 365, 475-481.
145. Johnsen, S. P.; Larsson, H.; Tarone, R. E.; McLaughlin, J. K.; Norgard, B.; Friis, S.; Sorensen, H. T. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study. Arch. Intern. Med., 2005, 165, 978-984.
146. Rao, G. H.; Johnson, G. G.; Reddy, K. R.; White, J. G. Ibuprofen protects platelet cyclooxygenase from irreversible inhibition by aspirin. Arteriosclerosis, 1983, 3, 383-388.
147. Patrignani, P.; Filabozzi, P.; Patrono, C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J. Clin. Invest., 1982, 69, 1366-1372.
148. Preston, F. E.; Whipps, S.; Jackson, C. A.; French, A. J.; Wyld, P. J.; Stoddard, C. J. Inhibition of prostacyclin and platelet thromboxane A2 after low-dose aspirin. N. Engl. J. Med., 1981, 304, 76-79.
149. Mitchell, J. A.; Warner, T. D. COX isoforms in the cardiovascular system: understanding the activities of non-steroidal antiinflammatory drugs. Nat. Rev. Drug Discov., 2006, 5, 75-86.
150. Violi, F.; Pignatelli, P. Aspirin resistance. Lancet, 2006, 367, 2059-2060.
151. Helgason, C.; Tortorice, K.; Winkler, S.; Penney, D.; Schuler, J.; McClelland, T.; Brace, L. Aspirin response and failure in cerebral infarction. Stroke, 1993, 24, 345-350.
152. Helgason, C.; Bolin, K.; Hoff, J.; Winkler, S.; Mangat, A.; Tortorice, K.; Brace, L. Development of aspirin resistance in persons with previous ischemic stroke. Stroke, 1994, 25, 2331-2336.
153. Hohlfeld, T.; Weber, A. A.; Junghans, U.; Schumacher, M.; Boucher, M.; Schror, K.; Siebler, M. Variable platelet response to aspirin in patients with ischemic stroke. Cerebrovasc. Dis., 2007, 24, 43-50.
154. Rao, G. H.; Michiels, J. J. Aspirin resistance: does it exist? Semin. Thromb. Hemost., 2007, 33, 210-214.
155. Weber, A. A.; Przytulski, B.; Schanz, A.; Hohlfeld, T.; Schror, K. Towards a definition of aspirin resistance: a typological approach. Platelets, 2002, 13, 37-40.
156. Schror, K.; Weber, A. A.; Hohlfeld, T. Aspirin "resistance". Blood Cells Mol. Dis., 2006, 36, 171-176.
157. Cambria-Kiely, J. A.; Gandhi, P. J. Aspirin resistance and genetic polymorphisms. J. Thromb. Thrombolysis, 2002, 14, 51-58.
158. Hillarp, A.; Palmqvist, B.; Lethagen, S.; Villoutreix, B. O.; Mattiasson, I. Mutations within the cyclooxygenase-1 gene in aspirin nonresponders with recurrence of stroke. Thromb. Res., 2003, 112, 275-283.
159. Li, Q.; Chen, B. L.; Ozdemir, V.; Ji, W.; Mao, Y. M.; Wang, L. C.; Lei, H. P.; Fan, L.; Zhang, W.; Liu, J.; Zhou, H. H. Frequency of genetic polymorphisms of COX1, GPIIIa and P2Y1 in a Chinese population and association with attenuated response to aspirin. Pharmacogenomics, 2007, 8, 577-586.
160. Takahashi, S.; Ushida, M.; Komine, R.; Shimodaira, A.; Uchida, T.; Ishihara, H.; Shibano, T.; Watanabe, G.; Ikeda, Y.; Murata, M. Platelet responsiveness to in vitro aspirin is independent of COX-1 and COX-2 protein levels and polymorphisms. Thromb. Res., 2008, 121, 509-517.
161. Halushka, M. K.; Walker, L. P.; Halushka, P. V. Genetic variation in cyclooxygenase 1: effects on response to aspirin. Clin. Pharmacol. Ther., 2003, 73, 122-130.
162. Lepantalo, A.; Mikkelsson, J.; Resendiz, J. C.; Viiri, L.; Backman, J. T.; Kankuri, E.; Karhunen, P. J.; Lassila, R. Polymorphisms of COX-1 and GPVI associate with the antiplatelet effect of aspirin in coronary artery disease patients. Thromb. Haemost., 2006, 95, 253-259.
163. Matijevic-Aleksic, N.; McPhedran, P.; Wu, K. K. Bleeding disorder due to platelet prostaglandin H synthase-1 (PGHS-1) deficiency. Br. J. Haematol., 1996, 92, 212-217.
164. Dube, J. N.; Drouin, J.; Aminian, M.; Plant, M. H.; Laneuville, O. Characterization of a partial prostaglandin endoperoxide H synthase-1 deficiency in a patient with a bleeding disorder. Br. J. Haematol., 2001, 113, 878-885.
165. de Weck, A. L.; Gamboa, P. M.; Esparza, R.; Sanz, M. L. Hypersensitivity to aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs). Curr. Pharm. Des., 2006, 12, 3347-3358.
166. Kiley, J.; Smith, R.; Noel, P. Asthma phenotypes. Curr. Opin. Pulm. Med., 2007, 13, 19-23.
167. Menzies, D.; Nair, A.; Meldrum, K. T.; Hopkinson, P.; Lipworth, B. J. Effect of aspirin on airway inflammation and pulmonary function in patients with persistent asthma. J. Allergy Clin. Immunol., 2008, 121, 1184-1189.e4.
168. Picado, C. Mechanisms of aspirin sensitivity. Curr. Allergy Asthma Rep., 2006, 6, 198-202.
169. Jenneck, C.; Juergens, U.; Buecheler, M.; Novak, N. Pathogenesis,
170. Pierzchalska, M.; Soja, J.; Wos, M.; Szabo, Z.; Nizankowska- Mogielnicka, E.; Sanak, M.; Szczeklik, A. Deficiency of cyclooxygenases transcripts in cultured primary bronchial epithelial cells of aspirin-sensitive asthmatics. J. Physiol. Pharmacol., 2007, 58, 207-218.
171. Kowalski, M. L.; Borowiec, M.; Kurowski, M.; Pawliczak, R. Alternative splicing of cyclooxygenase-1 gene: altered expression in leucocytes from patients with bronchial asthma and association with aspirin-induced 15-HETE release. Allergy, 2007, 62, 628-634.
172. Bunimov, N.; Smith, J. E.; Gosselin, D.; Laneuville, O. Translational regulation of PGHS-1 mRNA: 5′ untranslated region and first two exons conferring negative regulation. Biochim. Biophys. Acta, 2007, 1769, 92-105.
173. Gebauer, F.; Hentze, M. W. Molecular mechanisms of translational control. Nat. Rev. Mol. Cell Biol., 2004, 5, 827-835.
174. Grimm, D.; Kay, M. A. RNAi and Gene Therapy: A Mutual Attraction. Hematol. Am. Soc. Hematol. Educ. Program., 2007, 2007, 473-481.
175. Fire, A.; Xu, S.; Montgomery, M. K.; Kostas, S. A.; Driver, S. E.; Mello, C. C. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature, 1998, 391, 806-811.
176. Bumcrot, D.; Manoharan, M.; Koteliansky, V.; Sah, D. W. RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat. Chem. Biol., 2006, 2, 711-719.
177. de Fougerolles, A.; Vornlocher, H. P.; Maraganore, J.; Lieberman, J. Interfering with disease: a progress report on siRNA-based therapeutics. Nat. Rev. Drug Discov., 2007, 6, 443-453.
178. Schaffert, D.; Wagner, E. Gene therapy progress and prospects: Synthetic polymer-based systems. Gene Ther., 2008.